Retatrutide and Tirzepatide are investigational compounds and not approved for human consumption.
Is there a minimum commitment to join the program
Overall, 14% of GLP-1 users say they are now no longer using the medications due to the cost of the drugs
[4] Ultimately, the choice of GLP-1 agonist should be a collaborative decision between the patient and their healthcare provider, taking into account individual factors, treatment goals, and potential risks and benefits
In our continued exploration of GLP-1 (Glucagon-Like Peptide-1), we've already taken an in-depth look at its functions, production, and therapeutic importance in a [previous blog post] While GLP-1 offers numerous benefits, it is equally important to be aware of the potential side effects associated with GLP-1 medications